Alphamab Oncology has dosed the first subject in the randomised Phase III JSKN003-306 trial of its anti-human epidermal ...

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparatopic antibody-drug ...

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

The peritoneal cancer market is growing, as people become more aware of the disease and because diagnostic techniques and treatment choices improve. The market expansion also results from the rising ...

Section of Medicine, Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey, UK Metastasis from epithelial ovarian cancer can occur via the transcoelomic, haematogeneous, or lymphatic ...

Malignant ascites, a complication observed in terminal ovarian cancer, significantly contributes to poor quality of life and to mortality. Excess accumulation of fluid in the peritoneal cavity occurs ...

High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a ...

The completion of a new drug application for the combination of avutometinib and defactinib in KRAS-mutant ovarian cancer is expected to be finalized with the FDA by the end of the month.

At the Research Awards 2024, we had the pleasure of hearing from Professor Anna DeFazio AM, University of Sydney, who heads ...

ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines. To provide updated guidance regarding neoadjuvant chemotherapy (NACT) and primary cytoreductive surgery ...

Matthew J. Knarr of the Penn Ovarian Cancer Research Center, and lead author of the new analysis. "Its high mortality rate is due to the absence of early symptoms, resulting in 80% of patients being ...

Patients with relapsed ovarian cancer who had germline or somatic BRCA mutations saw greater OS with olaparib, according to ...